On Molecular Classification of Bladder Cancer: Out of One, Many

Aine, Mattias; Eriksson, Pontus; Liedberg, Fredrik; Höglund, Mattias; Sjödahl, Gottfrid

doi:10.1016/j.eururo.2015.07.021

Cited by 45 publications

(32 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the development of genome sequencing and bioinformatics, an increasing number of studies have focused on molecular biomarkers associated with standard pathological features to identify the risk stratification of patients, to guide treatment planning and ultimately to improve clinical outcome. 27,28 Until now, a plethora of single molecular biomarkers have been reported, [7][8][9] but only a few have been validated for clinical use or recommended by guidelines. [29][30][31] On the other hand, the predictive effect of a multiple gene signature has been highlighted.…”

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

141

118

View full text Add to dashboard Cite

The transition from non–muscle‐invasive bladder cancer (NMIBC) to muscle‐invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial‐mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT‐related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease‐free survival (DFS) than those with low risk scores. The EMT‐related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT‐related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT‐related gene signature that has tumour‐promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA.

show abstract

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

141

118

View full text Add to dashboard Cite

show abstract

“…21 Cases with uncertain behavior type, including PUNLMP, and with a topography code corresponding to vagina (ICD-4: C52.9) were censored at the time of diagnosis. Incident UCC cases were identified up to 31 December 2015, using ICD-O-3 morphology codes 8120, 8122, 8130 or 8131.…”

Section: Case Ascertainmentmentioning

confidence: 99%

“…Superficial UCC included papillary transitional/urothelial cell neoplasm of low malignant potential (PUNLMP) or carcinoma in situ (CIS) that was completely confined within the epithelium. 21 Cases with uncertain behavior type, including PUNLMP, and with a topography code corresponding to vagina (ICD-4: C52.9) were censored at the time of diagnosis. The remaining cases included topographic codes (ICD-O-3) corresponding to the bladder (C67), the kidney (C64-C65), the ureter (C66) and the urethra (C68).…”

Section: Case Ascertainmentmentioning

confidence: 99%

Dietary intake of nutrients involved in one‐carbon metabolism and risk of urothelial cell carcinoma: A prospective cohort study

Dugué

Brinkman

Hodge

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Nutrients involved in one-carbon metabolism may play a role in carcinogenesis through DNA replication, repair and methylation mechanisms. Most studies on urothelial cell carcinoma (UCC) have focused on folate. We sought to examine the association between B-group vitamins and methionine intake and UCC risk, overall and by subtype, and to test whether these associations are different for population subgroups whose nutritional status may be compromised. We followed participants in the Melbourne Collaborative Cohort Study (N = 41,513) for over 20 years and observed 500 UCC cases (89% originating in the bladder; superficial: 279, invasive: 221). Energy-adjusted dietary intakes of B vitamins (B1, B2, B3, B5, B6, B8, B9 and B12) and methionine were estimated from a 121-item food frequency questionnaire administered at baseline (1990-1994), using the residuals method. We used Cox regression models to compute hazard ratios (HRs) of UCC risk per standard deviation (SD) of log-transformed nutrient intakes and 95% confidence intervals, adjusted for potential confounders. We investigated associations by tumor subtype, and tested interactions with sex, country of birth, smoking and alcohol drinking. The risk of UCC appeared not to be associated with intake of B-group vitamins or methionine, and findings were consistent across tumor subtypes and across demographic and lifestyle characteristics of the participants. A potential interaction between vitamin B1 and alcohol drinking was observed (all participants: HR per 1 SD = 0.99 (0.91-1.09), never drinkers: HR = 0.81 (0.69-0.97), p-interaction = 0.02), which needs to be confirmed by other studies. Our findings do not indicate that dietary intake of nutrients involved in one-carbon metabolism are associated with UCC risk.

show abstract

“…Molecular characterization at the genetic level based on next generation sequencing data, suggested a new sub‐classification involving NMIBC and MIBC, based on mutation status of epithelial cytokeratins HIF‐1, EGFR, FGFR, ERB as well as PI‐3 kinase/AKT pathway . The presence of additional molecular disease subtypes has been suggested by various groups (as summarized in) nevertheless, with a consensus on clinical decision making not having been reached yet. Due to the increased BC heterogeneity and as the individual molecular profile has a significant impact on disease aggressiveness and drug response, therapeutic decision making based on the classical histopathological assessment of the tumor tissue is not always successful.…”

Section: Personalized Medicine In Bladder Cancermentioning

confidence: 99%

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Latosinska

Frantzi

Vlahou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of -omics-based approaches. Proteomics attract high interest, as proteins reflect a "real-time" dynamic molecular phenotype. Focusing on proteomics applications for personalized medicine, a literature search was conducted to cover: a) disease prevention, b) monitoring/ prediction of treatment response, c) stratification to guide intervention, and d) identification of drug targets. The review indicates the potential of proteomics for personalized medicine by also highlighting multiple challenges to be addressed prior to actual implementation. In oncology, particularly bladder cancer, application of precision medicine appears especially promising. The high heterogeneity and recurrence rates together with the limited treatment options, suggest that earlier and more efficient intervention, continuous monitoring, and the development of alternative therapies could be accomplished by applying proteomics-guided personalized approaches. This notion is backed by studies presenting biomarkers that are of value in patient stratification and prognosis, and by recent studies demonstrating the identification of promising therapeutic targets. Herein, we aim to present an approach whereby combining the knowledge on biomarkers and therapeutic targets in bladder cancer could serve as basis towards proteomics-guided personalized patient management.

show abstract

On Molecular Classification of Bladder Cancer: Out of One, Many

Cited by 45 publications

References 13 publications

An EMT‐related gene signature for the prognosis of human bladder cancer

An EMT‐related gene signature for the prognosis of human bladder cancer

Dietary intake of nutrients involved in one‐carbon metabolism and risk of urothelial cell carcinoma: A prospective cohort study

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Contact Info

Product

Resources

About